

Emily K Osterweil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7459554/publications.pdf>

Version: 2024-02-01

31
papers

3,409
citations

394421

19
h-index

610901

24
g-index

34
all docs

34
docs citations

34
times ranked

4224
citing authors

#	ARTICLE	IF	CITATIONS
1	Correction of Fragile X Syndrome in Mice. <i>Neuron</i> , 2007, 56, 955-962.	8.1	895
2	Mutations causing syndromic autism define an axis of synaptic pathophysiology. <i>Nature</i> , 2011, 480, 63-68.	27.8	546
3	Hypersensitivity to mGluR5 and ERK1/2 Leads to Excessive Protein Synthesis in the Hippocampus of a Mouse Model of Fragile X Syndrome. <i>Journal of Neuroscience</i> , 2010, 30, 15616-15627.	3.6	336
4	Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. <i>Journal of Clinical Investigation</i> , 2002, 109, 383-392.	8.2	259
5	A role for myosin VI in postsynaptic structure and glutamate receptor endocytosis. <i>Journal of Cell Biology</i> , 2005, 168, 329-338.	5.2	210
6	Lovastatin Corrects Excess Protein Synthesis and Prevents Epileptogenesis in a Mouse Model of Fragile X Syndrome. <i>Neuron</i> , 2013, 77, 243-250.	8.1	206
7	Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 2587-2592.	7.1	143
8	Myosin 1E interacts with synaptojanin-1 and dynamin and is involved in endocytosis. <i>FEBS Letters</i> , 2007, 581, 644-650.	2.8	137
9	Fragile X: Translation in Action. <i>Neuropsychopharmacology</i> , 2008, 33, 84-87.	5.4	94
10	Conserved hippocampal cellular pathophysiology but distinct behavioural deficits in a new rat model of FXS. <i>Human Molecular Genetics</i> , 2015, 24, 5977-5984.	2.9	92
11	Cell-Type-Specific Translation Profiling Reveals a Novel Strategy for Treating Fragile X Syndrome. <i>Neuron</i> , 2017, 95, 550-563.e5.	8.1	81
12	Convergence of Hippocampal Pathophysiology in <i>Syngap1</i> ^{+/Δ} and <i>Fmr1</i> ^{+/Δ} Mice. <i>Journal of Neuroscience</i> , 2015, 35, 15073-15081.	3.6	76
13	Perturbed proteostasis in autism spectrum disorders. <i>Journal of Neurochemistry</i> , 2016, 139, 1081-1092.	3.9	58
14	Sustained correction of associative learning deficits after brief, early treatment in a rat model of Fragile X Syndrome. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	57
15	Is metabotropic glutamate receptor 5 upregulated in prefrontal cortex in fragile X syndrome?. <i>Molecular Autism</i> , 2013, 4, 15.	4.9	50
16	Microbiome-derived carnitine mimics as previously unknown mediators of gut-brain axis communication. <i>Science Advances</i> , 2020, 6, eaax6328.	10.3	45
17	Negative Allosteric Modulation of mGluR5 Partially Corrects Pathophysiology in a Mouse Model of Rett Syndrome. <i>Journal of Neuroscience</i> , 2016, 36, 11946-11958.	3.6	41
18	Metabotropic glutamate receptor signaling is required for NMDA receptor-dependent ocular dominance plasticity and LTD in visual cortex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 12852-12857.	7.1	21

#	ARTICLE	IF	CITATIONS
19	Lovastatin, not Simvastatin, Corrects Core Phenotypes in the Fragile X Mouse Model. <i>ENeuro</i> , 2019, 6, ENEURO.0097-19.2019.	1.9	20
20	Activation of mGluR5 Induces Rapid and Long-Lasting Protein Kinase D Phosphorylation in Hippocampal Neurons. <i>Journal of Molecular Neuroscience</i> , 2010, 42, 1-8.	2.3	14
21	Excess ribosomal protein production unbalances translation in a model of Fragile X Syndrome. <i>Nature Communications</i> , 2022, 13, .	12.8	13
22	Lifting the Mood on Treating Fragile X. <i>Biological Psychiatry</i> , 2012, 72, 895-897.	1.3	7
23	The mGluR Theory of Fragile X: From Mice to Men. , 2017, , 173-204.		4
24	Identification and functional modelling of plausibly causative cis-regulatory variants in a highly-selected cohort with X-linked intellectual disability. <i>PLoS ONE</i> , 2021, 16, e0256181.	2.5	3
25	A Differential Effect of Lovastatin versus Simvastatin in Neurodevelopmental Disorders. <i>ENeuro</i> , 2020, 7, ENEURO.0162-20.2020.	1.9	1
26	FMRP and the Pathophysiology of Fragile X Syndrome. , 2016, , 113-128.		0
27	Upsetting the excitatory-inhibitory balance hypothesis of autism. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	0
28	<i>SHANK3</i> puts autism to sleep. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	0
29	A primate resource for autism research. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	0
30	Of mice, men, and <i>NLGN4</i> . <i>Science Translational Medicine</i> , 2019, 11, .	12.4	0
31	Seizing control of fragile X syndrome. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	0